



16th June, 2025

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Yarramshetty Krishna Rao has been appointed as Senior Vice President – Operations at Mekaguda of the Company w.e.f. 16th June, 2025.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 are as under:

Sl. No.	Particulars	
1	Name	Mr. Yarramshetty Krishna Rao
2	Reason for Change in Senior Management	Senior Vice President – Operations
3	Date of Appointment & Term of Appointment	16 th June, 2025 & Terms of appointment are as per the Company's Policy
4	Brief profile	Mr. Yarramshetty Krishna Rao has overall 33 years of experience in the leading Indian Bulk Drug/API Manufacturing Industries, with 20 years of experience as Unit Head. He was associated with Dr. Reddy's Laboratories Limited, Hyderabad, as Senior Director/Site Head - API manufacturing unit.
5	Disclosure of relationship between Directors	Not Applicable

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer